These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27863666)

  • 1. Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.
    Colombo G; Bortolotti F; Chiapponi V; Buttini F; Sonvico F; Invernizzi R; Quaglia F; Danesino C; Pagella F; Russo P; Bettini R; Colombo P; Rossi A
    Int J Pharm; 2016 Nov; 514(1):229-237. PubMed ID: 27863666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal powders of quercetin-β-cyclodextrin derivatives complexes with mannitol/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation.
    Papakyriakopoulou P; Manta K; Kostantini C; Kikionis S; Banella S; Ioannou E; Christodoulou E; Rekkas DM; Dallas P; Vertzoni M; Valsami G; Colombo G
    Int J Pharm; 2021 Sep; 607():121016. PubMed ID: 34411652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceutical characterization of praziquantel cocrystals and cyclodextrin complexes prepared by grinding.
    Cugovčan M; Jablan J; Lovrić J; Cinčić D; Galić N; Jug M
    J Pharm Biomed Anal; 2017 Apr; 137():42-53. PubMed ID: 28092854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life.
    Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM
    Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations.
    Schipper NG; Romeijn SG; Verhoef JC; Merkus FW
    Pharm Res; 1993 May; 10(5):682-6. PubMed ID: 8321831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of nasal powders of beta-cyclodextrin by insufflation.
    De Ascentiis A; Bettini R; Caponetti G; Catellani PL; Peracchia MT; Santi P; Colombo P
    Pharm Res; 1996 May; 13(5):734-8. PubMed ID: 8860429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.
    Invernizzi R; Quaglia F; Klersy C; Pagella F; Ornati F; Chu F; Matti E; Spinozzi G; Plumitallo S; Grignani P; Olivieri C; Bastia R; Bellistri F; Danesino C; Benazzo M; Balduini CL
    Lancet Haematol; 2015 Nov; 2(11):e465-73. PubMed ID: 26686256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Chen S; Karnezis T; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.
    de Jel DVC; Disch FJM; Kroon S; Mager JJ; Verdam FJ
    Angiogenesis; 2020 Aug; 23(3):271-274. PubMed ID: 32112177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.
    Ambrus R; Gieszinger P; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P; Bartos C
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32120992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of minoxidil/hydroxypropyl-β-cyclodextrin inclusion complex in aqueous alginate gel useful for alopecia management: Efficacy evaluation in male rat.
    Tricarico D; Maqoud F; Curci A; Camerino G; Zizzo N; Denora N; Cutrignelli A; Laquintana V; Lopalco A; la Forgia F; Fontana S; Franco M; Lopedota A
    Eur J Pharm Biopharm; 2018 Jan; 122():146-157. PubMed ID: 29079420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.
    Lebrin F; Srun S; Raymond K; Martin S; van den Brink S; Freitas C; Bréant C; Mathivet T; Larrivée B; Thomas JL; Arthur HM; Westermann CJ; Disch F; Mager JJ; Snijder RJ; Eichmann A; Mummery CL
    Nat Med; 2010 Apr; 16(4):420-8. PubMed ID: 20364125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and Biophysical Characterization of Quercetin Inclusion Complexes with β-Cyclodextrin Derivatives to be Formulated as Possible Nose-to-Brain Quercetin Delivery Systems.
    Manta K; Papakyriakopoulou P; Chountoulesi M; Diamantis DA; Spaneas D; Vakali V; Naziris N; Chatziathanasiadou MV; Andreadelis I; Moschovou K; Athanasiadou I; Dallas P; Rekkas DM; Demetzos C; Colombo G; Banella S; Javornik U; Plavec J; Mavromoustakos T; Tzakos AG; Valsami G
    Mol Pharm; 2020 Nov; 17(11):4241-4255. PubMed ID: 32986435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
    Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
    Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.
    Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation.
    Mennini N; Cirri M; Maestrelli F; Mura P
    Int J Pharm; 2016 Dec; 515(1-2):684-691. PubMed ID: 27825863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia.
    Penaloza A; Vekemans MC; Lambert C; Hermans C
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.